Today, Merck and the Dermapharm Holding SE have signed an agreement for the acquisition of all shares of Allergopharma. Both companies have published respective press releases.
We are very excited about this step as it ensures the long-term development of Allergopharma. Having won Dermapharm as a partner is the basis for this development.
Dermapharm is a German listed company which has allergic diseases as a strategic focus already today. Currently, Dermapharm produces and distributes anti-symptomatic products for allergy patients. It is the clear objective of Dermapharm to strengthen and grow products for allergy treatment. To achieve this, Allergopharma and our AIT products are the perfect partner.
Ownership of Allergopharma has not yet transferred to the Dermapharm Holding SE with the signing of the agreement. The transaction, which is expected to close by the end of the second quarter 2020, is subject to regulatory approval and satisfaction of other customary closing conditions.
Please find further information here: https://www.merckgroup.com/en/news/allergopharma-19-02-2020.html